Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4

Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Jitesh, Grandits, Melanie, Palhares, Lais C. G. F., Mele, Silvia, Nakamura, Mano, López-Abente, Jacobo, Crescioli, Silvia, Laddach, Roman, Romero-Clavijo, Pablo, Cheung, Anthony, Stavraka, Chara, Chenoweth, Alicia M., Sow, Heng Sheng, Chiaruttini, Giulia, Gilbert, Amy E., Dodev, Tihomir, Koers, Alexander, Pellizzari, Giulia, Ilieva, Kristina M., Man, Francis, Ali, Niwa, Hobbs, Carl, Lombardi, Sara, Lionarons, Daniël A., Gould, Hannah J., Beavil, Andrew J., Geh, Jenny L. C., MacKenzie Ross, Alastair D., Healy, Ciaran, Calonje, Eduardo, Downward, Julian, Nestle, Frank O., Tsoka, Sophia, Josephs, Debra H., Blower, Philip J., Karagiannis, Panagiotis, Lacy, Katie E., Spicer, James, Karagiannis, Sophia N., Bax, Heather J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130092/
https://www.ncbi.nlm.nih.gov/pubmed/37185332
http://dx.doi.org/10.1038/s41467-023-37811-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130092/
https://www.ncbi.nlm.nih.gov/pubmed/37185332
http://dx.doi.org/10.1038/s41467-023-37811-3

Ejemplares similares